Abstracts tagged "glucocorticoids"

Abstract Number: 1273 • ACR Convergence 2024
An Investigation of Traumatic Events and Mental Health in cSLE
Paris Moaf¹, Ashley Danguecan², Michelle Quilter³, Julie Couture⁴, Daniela Dominguez⁵, Lawrence Ng⁶, Asha Jeyanathan⁷, Reva Schachter⁸, Daphne Korczak⁹, Deborah Levy⁶, Linda Hiraki⁶ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ³Whyteman’s Brae Hospital, Kirkcaldy, United Kingdom, ⁴Centre mère-enfant Soleil du CHU de Québec, Québec, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁸Sickkids Toronto, Toronto, ON, Canada, ⁹Hospital for Sick Children, University of toronto, Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with substantial morbidity, particularly in childhood-onset SLE (cSLE). Mental health conditions such as depression and…
Abstract Number: 1991 • ACR Convergence 2024
Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Muhammad Bukhari¹, Ami Shah², Clifton Bingham³, Michelle Jones⁴ and Laura Cappelli¹, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Pittsburgh, PA
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) occurs in 3-7% of patients receiving ICI therapy for cancer. ICI-IA is routinely treated with corticosteroids, however, there…
Abstract Number: 2483 • ACR Convergence 2024
Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study
Yusuke Ushio¹, Hiromi Shimada², taichi miyagi³, Koichi Sugihara⁴, Mao Mizusaki⁵, Rina Mino⁵, Hayamasa yamaguchi⁵, Naoto Manabe⁵, Shusaku Nakashima² and Hiroaki Dobashi², ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, ⁵Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was demonstrated to be an alternative to glucocorticoids (GC) in the treatment of microscopic polyangiitis (MPA)/granulomatosis with polyangiitis…
Abstract Number: 0168 • ACR Convergence 2024
Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Tatsuya Atsumi¹, Hironari Hanaoka², Nobuo Nishijima³, Kohji Murakami⁴, Mariko Nio³, Tsutomu Urakawa³, Takaaki Fujimura³ and Hiroki Hayashi⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁴Nippon Shinyaku Co., Ltd., Tokyo, Japan, ⁵Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
Abstract Number: 1358 • ACR Convergence 2024
A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
Manyam Prudhvi Krishna¹, Sandeep Surendran¹, MITHUN CHALAKKARAYIL BHAGAVALDAS², Sundarakrishna Sai³, Sekhar V Easwar¹, Ronith S Kumar³ and Manu Pradeep¹, ¹Amrita Institute of Medical Sciences, Kochi, Kerala, India, ²Amrita Institute of Medical Sciences, ERNAKULAM, Kerala, India, ³Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
Background/Purpose: Steroids play a key role in treating rheumatic diseases due to their anti-inflammatory effects. However, long-term or high-dose use leads to side effects like…
Abstract Number: 2027 • ACR Convergence 2024
Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review
Adrián Martín-Gutiérrez¹, Javier Loricera², Fernando Lopez-Gutierrez³ and Ricardo Blanco-Alonso⁴, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Retroperitoneal fibrosis (RPF) is usually idiopathic (iRPF), but may be secondary to drugs, neoplasms, infections, or may be part of an IgG4-related disease. Our…
Abstract Number: 2486 • ACR Convergence 2024
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Shoichi Fukui¹, Naoki Iwamoto¹, Ayaka Umetsu², Momoko Okamoto², Keita Fujikawa², Akinari Mizokami², Takuya Tomokawa³, Kazusato Hara³, Yoshiro Horai³ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology, Japan Community Healthcare Organization (JCHO) Isahaya General Hospital, Isahaya, Japan, ³Department of Rheumatology, Sasebo City General Hospital, Sasebo, Japan, ⁴Nagasaki University, Nagasaki, Japan
Background/Purpose: Avacopan, a C5a receptor inhibitor, has emerged as a novel treatment for ANCA-associated vasculitis (AAV), providing an alternative to glucocorticoids1. Despite its promising potential,…
Abstract Number: L16 • ACR Convergence 2023
Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial
Linyi Peng¹, Yuxue nie¹, Jiaxin Zhou¹, Lijun Wu², Fang Wang³, Xiaomei Chen⁴, Jieqiong Li¹, Yu Peng¹, Hui Lu¹, Lidan Zhao¹, Mengtao Li¹, Yan Zhao¹, Xiaofeng Zeng⁵, Yunyun Fei¹ and Wen Zhang¹, ¹Peking Union Medical College Hospital，Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China, ²Xinjiang Uygur Autonomous Region People's Hospital, XinJiang, China, ³Beijing Hospital, Beijing, China, ⁴Xinjiang Uygur Autonomous Region People's Hospital, Wulumuqi, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibroinflammatory disease. Remission induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy…
Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Amit Saxena¹, Peter Izmirly², Jammie Law³, Cristina Sorrento³, H Michael Belmont⁴ and Jill Buyon⁵, ¹New York University Grossman School of Medicine, Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…
Abstract Number: 2028 • ACR Convergence 2023
Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact
Kevin Yip¹, Suellen Lyne², Vasilis Vasiliou³, David Katz⁴, Pamela Richards⁵, Joanna Tieu⁶, Rachel Black⁷, Susan Bridgewater⁸, Dorcas Beaton⁹, lara maxwell¹⁰, Jo Robson⁸, Sarah Mackie¹¹, Catherine Hill⁶ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²The Queen Elizabeth Hospital, Adelaide, Australia, ³Royal Holloway, University of London, London, United Kingdom, ⁴Sparrow Pharmaceuticals, Portland, OR, ⁵NA, Bristol, United Kingdom, ⁶The Queen Elizabeth Hospital, Woodville, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸University of the West of England, Bristol, United Kingdom, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of Ottawa, Ottawa, ON, Canada, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Healthcare research has historically been medically oriented, less focused on the patients' perspective that research shows can improve the quality of care. OMERACT advocates…
Abstract Number: 0782 • ACR Convergence 2023
Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies
Maria Dall'Era¹, Ernie Yap², Matt Truman², Lucy Hodge² and Neil Solomons³, ¹University of California San Francisco, San Francisco, CA, ²Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ³Neil Solomons Consulting Inc., Victoria, BC, Canada
Background/Purpose: Dual-immunosuppressive regimens consisting of high-dose glucocorticoids and higher doses ( >2 g/day) of mycophenolate mofetil (MMF) are still frequently used for the initial management…
Abstract Number: 2085 • ACR Convergence 2023
A Survey on Giant Cell Arteritis-Related Knowledge Among Internal Medicine Residents
Helina Maharjan¹, Muhammad Abdullah², Summia Matin Afridi³, Alsayed Osman⁴, Aleena Sammar⁵ and Ahmad Raja⁶, ¹Bassett Medical Center, Cooperstown, NY, ²Islamic International Medical College, Rawalpindi, Pakistan, ³Albany Medical Center, Albany, NY, ⁴AdventHealth Florida, Orlando, FL, ⁵Parkview Medical Center, Pueblo, CO, ⁶Mary Imogene Bassett Hospital, Evanston, IL
Background/Purpose: Giant Cell Arteritis (GCA) poses challenges in clinical practice, necessitating a deep understanding. Internal medicine residents play a crucial role in patient care and…
Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Brad Rovin¹, Jorge Ross Terres², Sophia Giang³, Thomas Schindler⁴, Armando Turchetta⁵, Jay Garg², Richard Furie⁶, William F. Pendergraft III² and Ana Malvar⁷, ¹Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Genentech, Inc., San Francisco, CA, ⁴F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶Northwell Health, Manhasset, NY, ⁷Hospital Fernandez, Buenos Aires, Argentina
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
Abstract Number: 2141 • ACR Convergence 2023
Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)
Kristina Lend¹, Jos W.R. Twisk², Nupur Kumar³, John Lampa⁴, Anna Rudin⁵, Merete Hetland⁶, Till Uhlig⁷, Dan Nordstrom⁸, Mikkel Østergaard⁹, Marte Schrumpf Heiberg¹⁰, Espen A Haavardsholm¹⁰, Bjorn Gudbjornsson¹¹, Tuulikki Sokka-Isler¹², Gerdur Maria Grondal¹³, Kim Hørslev-Petersen¹⁴, Michael Nurmohamed², Ronald van Vollenhoven² and Johan Frostegård³, ¹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Stockholm County, Hãsselby, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Helsinki University Hospital, Helsinki, Finland, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹²Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹⁴University of Southern Denmark, Odense, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
Abstract Number: 1055 • ACR Convergence 2023
Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
Vanissa Savarimuthu¹, Alexandra Ladouceur², Oliver Terry¹, Janet Roberts³, Janet Pope⁴, Thomas Appleton⁴, Sabrina Hoa⁵, Aurore Fifi-Mah⁶, Nancy Maltez⁷, Alexandra Saltman⁸, Megan Himmel⁸, Ines Colmegna⁹, Lindsay Cho¹⁰, Emma Schmidt¹⁰, Claudie Berger¹¹, Thomas Barnetche¹², Lourdes Gonzalez Arreola¹³, Carrie Ye¹⁴, Shahin Jamal¹⁵ and Marie Hudson¹⁶, ¹McGill University, Montreal, QC, Canada, ²Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Montreal, Brossard, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷The Ottawa Hospital, Ottawa, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, BC, Canada, ¹¹RI-MUHC, Montreal, QC, Canada, ¹²Bordeaux University Hospital, Bordeaux, France, ¹³Arthritis Research Canada, Vancouver, BC, Canada, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶McGill University, Montréal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. A drawback of ICI therapy is their off-target effects known as immune-related adverse events…

« Previous Page
1
…
6
7
8
9
10
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].